Investors

Exits and Awards

We took two companies public and exited six companies.
Read more

IR Contact Details

Judith Kleinman
Director, Investor Relations and Corporate Communications
The Trendlines Group
+972.72.260.7000
judith@trendlines.com

 


Romil Singh / Reyna Mei
Financial PR Pte Ltd
+65 6438 2990
investors@trendlines.com

FAQs

How does Trendlines support its portfolio companies?

From the time of our initial investment, we are involved in nearly all aspects of our portfolio companies from technology development to business building.

Trendlines is a leader in providing technology and business development support to early-stage companies in the fields of medical and agricultural technologies. In addition to human capital, we provide our portfolio companies with R&D, business development, and administrative support such as physical facilities and legal and financial services. We believe that this high support-level allows our companies to focus on developing their technology, product and markets, thereby reducing risk and increasing the chances for success.

We provide a range of services to our portfolio companies during their first years such as:

  • technology support, including R&D;
  • business development, market and commercialization strategy and support;
  • funding strategy;
  • financial support; and
  • marketing communications.

What is Trendlines’ business model?

Trendlines focuses on creating and developing medical and agricultural technology companies with a view toward successful exits, which may include sales such as merger and acquisition transactions, listing on public stock exchanges, and other dispositions of our holdings.

In addition, 17 of our portfolio companies are generating revenue.

What is Trendlines’ organizational structure?

Trendlines operates principally through the 2 operating subsidiaries, namely, Trendlines Medical and Trendlines Agtech, as well as through its own internal innovation center, Trendlines Labs.

Trendlines Medical is a technology incubator that was established in 1995, of which we acquired control in 2007. Trendlines Medical focuses on the discovery and development of novel and disruptive medical devices and technologies.

Trendlines Agtech is a technology incubator that was established in 1992, of which we acquired control in 2007. In 2011, Trendlines Agtech began to focus on the discovery and development of new agricultural and food technologies. Since 2011, the companies established by Trendlines Agtech have focused on increasing food yields and reducing costs with an emphasis on sustainability.

Trendlines Labs was established as a business unit of our Company in 2011 to invent and develop technologies for sale or licensing to others or for transfer to our incubators for further development and commercialization. Trendlines Labs conducts research and development activities to create new technologies, either as principal or in collaboration with global and local companies and partners, to address unmet market needs.

What are Trendlines’ competitive strengths?

Extensive network of relationships
We have cultivated an extensive network of relationships with entrepreneurs, inventors, technology transfer organizations, lawyers, patent attorneys, accountants, investment bankers, venture capitalists, and commercial enterprises in the medical and agricultural technologies markets. Through our extensive network of contacts, we are able to generate quality deal flow as well as undertake fund-raising activities.

Our network of relationships introduces 450 to 500 opportunities for our review annually. Approximately 45 opportunities a year receive in-depth attention, of which we seek to support and invest in 8 to 10. We have raised approximately US$25 million in equity since our establishment in 2007 to support our activities.

Physical facilities and environment to support our portfolio companies
During their first 2 to 3 years of operations, our portfolio companies are housed in one of our two incubator facilities. Our offices provide portfolio companies with a comfortable space in an entrepreneurial environment. The entrepreneurs benefit from working in close proximity with one another as it creates an environment that encourages cooperation, sharing ideas, brainstorming, and learning from one another. By working physically in one of our incubators, the companies have direct access to our extensive support structure, as well as to shared laboratories and equipment. Having the companies in our facilities increases our ability to monitor a company’s progress and to intervene, assist, and support as required.

Strong management team and track record
We have a strong management team with deep experience in creating, investing in, and developing companies to exit. Our Chief Executive Officers and Chairmen are both U.S.-born and educated and have lived in Israel for decades. Each has over 25 years of experience in investing, business development and bringing technologies to international markets, including in North America and China. Our key executive officers and staff are highly skilled; some hold advanced degrees in the fields of medicine, dentistry, plant genetics, electrical engineering, biomedical engineering, and business administration.

We believe providing extensive technology and business support is a necessity to successfully establish and grow young portfolio companies. We have assembled a team that understands global markets and possesses the ability to bridge cultures to build businesses.

Leveraging on their collective experience, our management team is able to develop and execute exit strategies for our portfolio companies. In this regard, since our establishment in 2007, we have taken two of our portfolio companies, FlowSense Medical and E.T. View, public on the TASE by way of reverse mergers and led four other portfolio companies (PolyTouch Medical, Inspiro Medical, Innolap Surgical, and one undisclosed) through successful acquisitions or sales to multinational corporations.

Effective use of funds
We initially fund our portfolio companies with what might be considered small amounts of capital so as to be highly efficient in our use of capital. Our ability to successfully limit the amount of capital that we put to work is predicated, in part, upon the fact that our portfolio companies, for at least their first 2 to 3 years, are located in our facilities and are extensively supported by our staff.

In addition, as a result of the franchises granted to Trendlines Medical and Trendlines Agtech by the Israeli government, we are able to leverage our portfolio investments with R&D grants from the Israeli government through the Technological Incubator Program (TIP). A typical investment of approximately US$98,000 is matched by the government in the form of contingent grants to a new company of approximately US$557,000.

Strong reputation and brand
Over the years, Trendlines Medical has twice been named the best incubator in Israel by the Israel’s Office of the Chief Scientist (OCS) and five of our portfolio companies have been named the best start-ups of the year by the OCS. Together with our track record of successful companies and exits, and the events that we sponsor, we believe we have built a reputation as being one of the best incubator organizations in Israel.

What are Trendlines’ strategies and future plans?

Our strategies and future plans for the continued growth of our business are as follows:

  • Follow-on investments in our portfolio companies
  • Expansion of our operations into new markets
  • Expansion of Trendlines Labs
  • Operational expenses to support and increase our number of portfolio companies

Exits and Awards

We took two companies public and exited six companies.
Read more

IR Contact Details

Judith Kleinman
Director, Investor Relations and Corporate Communications
The Trendlines Group
+972.72.260.7000
judith@trendlines.com

 


Romil Singh / Reyna Mei
Financial PR Pte Ltd
+65 6438 2990
investors@trendlines.com

Copyright 2017 The Trendlines Group

Delivered by Investis – link to website (opens in a new window)